SCHEMBL6433645

SCHEMBL6433645

NC(=O)C[S+]([O-])Cc1ccco1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.46
ALDH1A1 P00352 5/20 0.40
GAA P10253 3/20 0.38
KMT2A Q03164 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
LMNA P02545 2/20 0.38
POLB P06746 1/20 0.38
APEX1 P27695 1/20 0.38
TAS2R14 Q9NYV8 1/20 0.37
EPHX2 P34913 3/20 0.37
CYP2C19 P33261 1/20 0.37
SLC1A3 P43003 1/20 0.37
SLC1A2 P43004 1/20 0.37
SLC1A1 P43005 1/20 0.37
USP2 O75604 1/20 0.37
ALOX15 P16050 1/20 0.37
HSD17B10 Q99714 1/20 0.37
MEN1 O00255 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9519142 0.85 ALDH1A1 (0.41) ALOX5ALDH1A1KMT2ATDP1L3MBTL1
SCHEMBL9083176 0.83 ALDH1A1 (0.40) ALOX5ALDH1A1GAAKMT2ATDP1
SCHEMBL23124452 0.80 ALDH1A1 (0.44) ALDH1A1GAATDP1L3MBTL1POLB
SCHEMBL10526899 0.77 TSHR (0.46) ALDH1A1LMNAPOLBUSP2HSD17B10
SCHEMBL9194241 0.76 HSD17B10 (0.51) ALDH1A1KMT2ATDP1L3MBTL1LMNA
SCHEMBL2211037 0.75 CYP2C19 (0.35) ALDH1A1KMT2ATDP1POLBCYP2C19
SCHEMBL17038874 0.74 ALDH1A1 (0.45) ALOX5ALDH1A1KMT2ATDP1L3MBTL1
SCHEMBL8445238 0.74 POLB (0.40) ALOX5ALDH1A1GAAKMT2ATDP1
SCHEMBL3324604 0.73 POLB (0.55) ALDH1A1GAAKMT2ALMNAPOLB
SCHEMBL2100052 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005007107-A2 HISTAMINE AND CCK2/GASTRIN RECEPTOR BLOCKADE IN THE TREATMENT OF ACID-PEPTIC DISEASE AND CANCER UNIVERSITY OF MASSACHUSETTS (US) 2005-01-27 WO disclosed
EP-1294367-A2 ORAL COMPOSITIONS COMPRISING HOST-RESPONSE MODULATING AGENT The Procter & Gamble Company (US) 2003-03-26 EP disclosed
WO-2002002096-A2 ORAL COMPOSITIONS COMPRISING HOST-RESPONSE MODULATING AGENT THE PROCTER & GAMBLE COMPANY (US) 2002-01-10 WO disclosed
EP-0582304-B1 Methods of producing amino butene derivatives FUJIREBIO KK (JP) 1998-04-01 EP disclosed
US-5616711-A REACTING BUTENE DERIVATIVE TO AN AMIDE DERIVATIVE; USEFUL AS INTERMEDIATES FOR PRODUCING ANTIULCER DRUGS FUJIREBIO INC. (JP) 1997-04-01 US disclosed
EP-0582304-A2 Methods of producing amino butene derivatives FUJIREBIO Inc. (JP) 1994-02-09 EP disclosed
EP-0318036-A2 Phenoxypropyl derivatives FUJIREBIO KABUSHIKI KAISHA (JP) 1989-05-31 EP disclosed
EP-0282077-A2 Pyridyloxy derivatives FUJIREBIO KABUSHIKI KAISHA (JP) 1988-09-14 EP disclosed